Keyphrases
ENGOT
80%
Progression-free Survival
60%
Bevacizumab
58%
Tumor
48%
Olaparib
48%
Ovarian Cancer
41%
Meta-analysis
40%
Systematic Meta-analysis
40%
Recurrent Ovarian Cancer
40%
Computed Tomography
40%
PET-MRI
40%
Confidence Interval
39%
Cervical Cancer
38%
Homologous Recombination Deficiency
38%
Overall Survival
35%
Radiotherapy
33%
Advanced Ovarian Cancer
25%
Image Guidance
25%
Gynecological Cancer
25%
Phase II Trial
24%
Gynecologic Malignancies
23%
Multi-parameter
23%
Newly Diagnosed
21%
Vulvar Squamous Cell Carcinoma
21%
Hepatoid Adenocarcinoma
20%
Sequence Method
20%
Cancer Population
20%
Shallow Whole Genome Sequencing (sWGS)
20%
Clinical Risk
20%
BRCA mutation
20%
Toxicity Analysis
20%
Gemcitabine
20%
Routine Surveillance
20%
Implanted Markers
20%
Probe Pressure
20%
BRCA2 mutation
20%
Motion Management
20%
Vulvar Cancer
20%
Ov16
20%
Niraparib
20%
Maintenance Treatment
20%
High-grade Ovarian Cancer
20%
Programmed Death-ligand 1 (PD-L1)
20%
Symptom Analysis
20%
Lung
20%
Phantom
20%
Correlated Images
20%
Respiration
20%
One-stop-shop
20%
Adaptive Radiotherapy
20%
Medicine and Dentistry
Ovarian Cancer
85%
Progression Free Survival
76%
Neoplasm
61%
Bevacizumab
58%
Cervical Cancer
52%
Olaparib
48%
Overall Survival
43%
Recurrent Ovarian Cancer
40%
Positron Emission Tomography - Magnetic Resonance Imaging
40%
Radiation Therapy
38%
Homologous Recombination
38%
BRCA1
32%
Female Genital Tract Cancer
27%
Positron Emission Tomography-Computed Tomography
26%
Computer Assisted Tomography
24%
Disease
24%
Fluorodeoxyglucose F 18
22%
Cancer
22%
Image-Guided Intervention
22%
Maintenance Therapy
21%
Radiation Therapy Planning
20%
Vulva Carcinoma
20%
Meta-Analysis
20%
Systematic Review
20%
Adaptive Radiotherapy
20%
Fetoprotein
20%
Adenocarcinoma
20%
Symptom
20%
Exportin 1
20%
Selinexor
20%
Volunteer
20%
Cone Beam Computed Tomography
20%
BRCA2
20%
Niraparib
20%
Whole Genome Sequencing
20%
Lung Cancer
20%
Gemcitabine
20%
Stereotactic Radiotherapy
20%
Hazard Ratio
17%
Endometrial Cancer
16%
Adverse Event
14%
DNA Binding
14%
Malignant Neoplasm
12%
Carboplatin
11%
Stereotactic Body Radiation Therapy
11%
Doxorubicin
10%
Four Dimensional Computed Tomography
10%
Positron Emission Tomography
10%
Patient Population
10%
Magnetic Resonance Imaging
10%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Progression Free Survival
56%
Bevacizumab
42%
Olaparib
40%
Overall Survival
35%
Malignant Neoplasm
24%
Programmed Cell Death
20%
Adenocarcinoma
20%
Gemcitabine
20%
Symptom
20%
Niraparib
20%
Fetoprotein
20%
Selinexor
20%
Exportin 1
20%
Fluorodeoxyglucose F 18
20%
Disease
16%
Endometrium Cancer
16%
Adverse Event
14%
Prevalence
12%
Neoplasm
12%
Uterine Cervix Cancer
12%
Placebo
7%
Carboplatin
7%
Human Papillomavirus
6%
